Urogen Pharma (NASDAQ:URGN) Issues Earnings Results

Urogen Pharma (NASDAQ:URGN) released its quarterly earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.14), FiscalAI reports. The business had revenue of $89.00 million during the quarter, compared to the consensus estimate of $89.92 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• ZUSDURI revenue reached $68 million, up 35% sequentially. Prescribers increased to 662, repeat prescribers rose to 331, and management expects further quarter-over-quarter revenue growth in Q4 despite typical holiday seasonality.
• Management said the launch remains early, with broad adoption still developing: repeat prescribers were 50% of total writers, and the company estimated only a little over 10% of its core target urologists had prescribed ZUSDURI. It plans to expand patient-awareness efforts around mid-2027, while citing reimbursement confidence and practice workflows as adoption hurdles.
• JELMYTO revenue was $21 million, down from $22 million in Q2, and full-year revenue guidance was revised to approximately $90 million. The company cited a one-time $1.5 million gross-to-net adjustment and competition from clinical trials that is weighing on patient starts.
• The FDA accepted UGN-103’s NDA and set a June 14, 2027 PDUFA date; UroGen plans a potential launch in 2028, subject to approval and a permanent J-code. The company also expects to complete UGN-104 enrollment by year-end or early 2027, and has dosed the first patient in the UGN-501 Phase I trial.
• UroGen reported $90.5 million in cash and marketable securities, plus $117 million in accounts receivable, and management expects profitability and positive cash flow in Q4 2026. Operating expenses are now expected toward the upper end of the $260 million–$270 million guidance range.

Urogen Pharma Price Performance

Shares of URGN stock opened at $28.74 on Thursday. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -14.52 and a beta of 1.68. The business has a fifty day moving average of $39.60 and a 200 day moving average of $31.46. Urogen Pharma has a 1 year low of $16.50 and a 1 year high of $50.81.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group restated a “neutral” rating and set a $44.00 price target on shares of Urogen Pharma in a research note on Wednesday, July 15th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Urogen Pharma in a research report on Thursday, September 10th. UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. TD Cowen lifted their target price on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research report on Wednesday, October 28th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Urogen Pharma has a consensus rating of “Moderate Buy” and an average target price of $52.38.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 871 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total transaction of $37,383.32. Following the sale, the insider owned 59,882 shares in the company, valued at approximately $2,570,135.44. The trade was a 1.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Chris Degnan sold 2,202 shares of the stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the transaction, the chief financial officer directly owned 4,561 shares in the company, valued at $167,343.09. This represents a 32.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 65,269 shares of company stock valued at $3,037,646. 4.80% of the stock is owned by company insiders.

Key Stories Impacting Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: ZUSDURI generated $68 million in third-quarter revenue, up 35% from the prior quarter. Repeat prescribers also rose to 50% of ZUSDURI writers, suggesting growing adoption. The Gel That Became a Business
• Positive Sentiment: The FDA accepted UroGen’s UGN-103 application for review and set a June 14, 2027 PDUFA date. The company also dosed the first patient in its UGN-501 Phase 1 trial, adding potential future pipeline milestones. UroGen Q3 2026 results and highlights
• Neutral Sentiment: UroGen reported a quarterly loss of $0.03 per share and revenue of $89 million. The loss was narrower than a year earlier, though reported results were below analyst expectations. UroGen Q3 earnings results
• Negative Sentiment: The company cut its FY2026 guidance. That outlook reduction, alongside the earnings miss, appears to have overshadowed ZUSDURI’s sales growth and weighed on investor sentiment. UroGen stock and guidance report

Urogen Pharma Company Profile

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.